Biological Information

Background Information:

Neuropeptide FF receptor family is a member of the G protein-coupled receptor superfamily containing two subtypes, NPFF1 and NPFF2. NPFF1 is broadly distributed in the central nervous system, NPFF2 is present in high density in spinal cord. NPFF receptors and their endogenous ligand are responsible for hormonal modulation, food intake, thermoregulation and nociception through modulation of the opioid system where it has pro-nociceptive effects, primarily through the NPFF1, and anti-nociceptive effects, primarily through the NPFF2. Selective agonists or antagonists for NPFF receptors may be explored as novel treatments for relevant human disorders, such as neuropathic pain.

PathHunter β-Arrestin GPCR cell lines are engineered to co-express the ProLink™ (PK) tagged GPCR and the Enzyme Acceptor (EA) tagged β-Arrestin. Activation of the GPCR-PK induces β-Arrestin-EA recruitment, forcing complementation of the two β-galactosidase enzyme fragments (EA and PK). The resulting functional enzyme hydrolyzes substrate to generate a chemiluminescent signal.

Family:

GPCR

Sub Family:

Neuropeptide FF / Neuropeptide AF

Class:

Class A

Coupling:

Gi/Go

Protein Name:

NPFF1

Uniprot Number:

Q9GZQ6

Protein Aliases:

RFamide-related peptide receptor OT7T022

Gene Name:

NPFFR1

Gene ID:

64106

Gene Aliases:

GPR147|NPFF1

Accession Number:

NM_022146

Organism:

Human

Cell Type:

CHO-K1

Assay Information

Assay Type:

Functional

Assay Sub Type:

Cell Based

Functional Mode:

Antagonist

β-Arrestin Isoform:

β-Arrestin-2

Testing Information

Control Inhibitor:

RF 9

Control Activator:

RFRP-3

Test Concentration / Dose:

Eurofins will provide IC/EC50 calculation if 10 concentrations are selected

Test Sample Requirements:

40uL of a 1000X stock for the first assay and 2uL for each additional assay (assay = 1 target, 1 readout, 1 mode)

Minimum Order Quantity:

20

Turnaround Time

Standard:

15 Business Days

Clinical Relevance

Adverse / Beneficial Action:

Neuropeptide FF1 receptor has been reported to be explored as novel treatments for relevant neuropathic pain.

Additional Information

Brand:

LeadHunter

Testing Location:

USA - Fremont, CA